RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | 24.12M | 26.22M | 27.92M | 28.27M | 27.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.12M | 26.22M | 27.92M | 28.27M | 27.56M |
| Cost of Revenue | 10.39M | 11.34M | 12.41M | 12.63M | 12.94M |
| Gross Profit | 13.72M | 14.88M | 15.51M | 15.64M | 14.62M |
| SG&A Expenses | 15.56M | 15.62M | 15.91M | 15.73M | 14.93M |
| Depreciation & Amortization | 477.80K | 508.80K | 509.40K | 534.40K | 537.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.43M | 27.47M | 28.83M | 28.90M | 28.41M |
| Operating Income | -2.32M | -1.25M | -909.60K | -625.20K | -848.70K |
| Income Before Tax | -672.10K | -1.34M | -1.00M | -721.10K | -948.60K |
| Income Tax Expenses | -112.40K | -321.50K | -226.20K | -118.10K | -238.30K |
| Earnings from Continuing Operations | -0.56 | -1.01 | -0.77 | -0.60 | -0.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -559.50K | -1.01M | -774.80K | -602.70K | -710.20K |
| EBIT | -2.32M | -1.25M | -909.60K | -625.20K | -848.70K |
| EBITDA | -1.79M | -696.40K | -356.40K | -45.40K | -250.90K |
| EPS Basic | -0.25 | -0.46 | -0.35 | -0.27 | -0.32 |
| Normalized Basic EPS | -0.67 | -0.38 | -0.28 | -0.20 | -0.27 |
| EPS Diluted | -0.25 | -0.46 | -0.36 | -0.28 | -0.33 |
| Normalized Diluted EPS | -0.67 | -0.38 | -0.28 | -0.20 | -0.27 |
| Average Basic Shares Outstanding | 8.85M | 8.85M | 8.85M | 8.85M | 8.85M |
| Average Diluted Shares Outstanding | 8.85M | 8.85M | 8.85M | 8.85M | 8.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
